Breakthrough in Oral Squamous Cell Carcinoma Treatment through Immunostimulatory Nanovaccine

Strategic Insights -

A new research study published in Aggregate journal presents a promising approach to overcome current limitations in immune checkpoint blockade (ICB) therapies for treating oral squamous cell carcinoma (OSCC). The researchers from Sichuan Cancer Hospital & Institute developed an immunostimulatory nanovaccine using tetrahedral framework nucleic acids (tFNAs) as a carrier for stable and efficient delivery of CpG oligonucleotide. When combined with a PD-1 inhibitor, the nanovaccine effectively activated antigen-presenting cells (APCs), resulting in a substantial boost in infiltration of cytotoxic T cells in both lymph nodes and tumor tissues, thereby executing a potent antitumor effect and inhibiting the progression of OSCC tumors in C3H mouse.

Key Takeaways:

  • The research highlights the challenges faced by tumor vaccines in cancer immunotherapy, including potential mutation risks, rapid elimination, and low in vivo delivery efficiency.
  • The immunostimulatory nanovaccine developed in this study uses tetrahedral framework nucleic acids (tFNAs) as a carrier for stable and efficient delivery of CpG oligonucleotide.
  • The combination of the nanovaccine with PD-1 inhibitor effectively activates antigen-presenting cells (APCs), resulting in a substantial boost in infiltration of cytotoxic T cells in both lymph nodes and tumor tissues.
  • The study provides new avenues for future clinical practice in overcoming current ICB limitations in OSCC immunotherapy.
  • The researchers involved in the study include Xueting Yang, Yun Wang, Yan Yang, Sicheng Zhang, Dianri Wang, Yi Luo, Chunyan Shui, Yongcong Cai, Ruoyi Yang, Shuang Dong, Mu Yang, Yunfeng Lin, and Chao Li.
  • The study was conducted at the Sichuan Cancer Hospital & Institute, Sichuan Clinical Research Center for Cancer, and the Sichuan Cancer Center University of Electronic Science and Technology of China.

Statistics:

  • 2025: The year in which the research study was published.
  • 6(7): The issue and page numbers of the Aggregate journal where the research study was published.
  • n/a: The number of authors listed in the research study, excluding the corresponding author.
  • 10.1002/agt2.70061: The DOI reference number for the research study published in the Aggregate journal.
  • 66: The page number of the Vaccine Weekly news article reporting on the research study.

Sources:

  • Xueting Yang, et al. Immunostimulatory DNA Tetrahedron-Based Nanovaccine Combined With Immune Checkpoint PD-1 Blockade for Boosting Systemic Immune Responses Against Oral Squamous Cell Carcinoma. Aggregate, 2025,6(7):n/a-n/a.
  • NewsRx. Research in the Area of Oral Squamous Cell Carcinoma Reported from Sichuan Cancer Hospital & Institute (Immunostimulatory DNA Tetrahedron-Based Nanovaccine Combined With Immune Checkpoint PD-1 Blockade for Boosting Systemic Immune Responses ...). Vaccine Weekly. August 6, 2025; p 66.